Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M File

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
Clinical Therapeutics|July 31, 2017
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive PathogensDavid B Huang, Thomas M File, Antoni Torres, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2015
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trialsMaria Taboada, David Melnick, Joseph P Iaconis, et al.
Chest|May 12, 2004
Guidelines for empiric antimicrobial prescribing in community-acquired pneumoniaThomas M File, Javier Garau, Francesco Blasi, et al.
Surgical Infections|October 6, 2005
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative studyTimothy C Fabian, Thomas M File, John M Embil, et al.
The Journal of Infectious Diseases|October 5, 2013
Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumoniaRobert L Sherwin, Sharon Gray, Ronika Alexander, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2016
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trialsMaria Taboada, David Melnick, Joseph P Iaconis, et al.
Diagnostic Microbiology and Infectious Disease|November 7, 2017
The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogensDavid B Huang, Leonard R Duncan, Robert K Flamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 12, 2010
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumoniaThomas M File, Donald E Low, Paul B Eckburg, et al.
The American Journal of Medicine|July 5, 2005
A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteriaThomas G Slama, Alpesh Amin, Stephen A Brunton, et al.
Antimicrobial Agents and Chemotherapy|December 10, 2014
Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trialsThomas P Lodise, Antonio R Anzueto, David J Weber, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Clinical Therapeutics|July 31, 2017
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive PathogensDavid B Huang, Thomas M File, Antoni Torres, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2015
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trialsMaria Taboada, David Melnick, Joseph P Iaconis, et al.
Chest|May 12, 2004
Guidelines for empiric antimicrobial prescribing in community-acquired pneumoniaThomas M File, Javier Garau, Francesco Blasi, et al.
Surgical Infections|October 6, 2005
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative studyTimothy C Fabian, Thomas M File, John M Embil, et al.
The Journal of Infectious Diseases|October 5, 2013
Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumoniaRobert L Sherwin, Sharon Gray, Ronika Alexander, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2016
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trialsMaria Taboada, David Melnick, Joseph P Iaconis, et al.
Diagnostic Microbiology and Infectious Disease|November 7, 2017
The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogensDavid B Huang, Leonard R Duncan, Robert K Flamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 12, 2010
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumoniaThomas M File, Donald E Low, Paul B Eckburg, et al.
The American Journal of Medicine|July 5, 2005
A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteriaThomas G Slama, Alpesh Amin, Stephen A Brunton, et al.
Antimicrobial Agents and Chemotherapy|December 10, 2014
Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trialsThomas P Lodise, Antonio R Anzueto, David J Weber, et al.
Pageof 16